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INTRODUCTION 
Celecoxib is a breakthrough for pain relievers under the 
trade name Celebrex®, which is a Non-Steroid Anti-
Inflammatory drug (NSAID) with its activity as an analgesic, 
antipyretic and anti-inflammatory. This Celecoxib includes 
Non-Steroid Anti-Inflammatory which selectively inhibit 
the enzyme cyclooxygenase 2 (COX-2) and was permitted 
to circulate in 1999 (Meek et al., 2010). In the form of white 
powder, difficult to dissolve in water, dissolved in 
methanol, ethyl acetate and acetone (Raval et al., 2010). 
Refoxocib is also classified as a selective NSAID against the 
COX-2 enzyme in which its chemical structure is similar to 
celecoxib. Refoxocib was introduced in 1999 and obtained 
permission to circulate in Indonesia starting from 2001. 
However, this drug has been withdrawn from circulation 
since 2004 due to an increase in cardiovascular risk in the 
form of heart attacks and strokes due to thrombotic 
events. Celecoxib and Refoxocib can be used as uric acid 
medicine because Refoxocib is a circulation permit (Zarghi 
& Arfaei, 2011). 
After being withdrawn, this study was conducted to see the 
effect of Celecoxib on uric acid levels in white mice. Uric 
acid is the final product of purine degradation in the body. 
Uric acid including weak acid with pKa 5.4 in the form of 
white crystals, odorless and tasteless, and very difficult to 
dissolve in water (Hediger, 2004). Uric acid is produced in 
the liver, bone marrow and muscles. In these organs, there 
are anti-oxidase enzymes that can convert purines into uric 
acid, mainly with the presence of xanthine oxidase (Murray, 
2012; Suyono, 2001). 
Uric acid disorders are caused by high levels of uric acid in 
the blood, causing a buildup of crystals in joint areas that 
can cause pain (Murray, 2012; Milind et al., 2013). To 
reduce this pain is usually given NSAID (Ong et al., 2007). 
However, there have been no clinical reports about the 
effect of Celecoxib on uric acid levels. The purpose of this 
study was to find out the effect of celecoxib on blood uric 
acid levels of female white mice with the Enzymatic 
Photometric method. The results of this study are 
expected to be additional input for pharmacists, 
researcher, and physician in providing drug treatment 
appropriately and rationally so that the risk of errors in the 
use of NSAID drugs can be minimized and drug interactions 
can be avoided. 
 
MATERIAL AND METHODS 
Tools and Materials 
The equipment used includes Analytical scales, animal 
scales, animal cage, oral needles, measuring cup, 
micropipette, drop pipette, test tube, test tube rack, 
Erlenmeyer, beker glass, centrifuge, centrifuge tube, 
spatula, mortar and stamfer, Philips 50/60 Hz blender, 
tweezers, label, knife, spectrophotometer, Genesis 
Thermospectronic 20. The materials used in this study 
were Celecoxib (Celebrex®), Na-CMC, distilled water, 
fresh cow liver, reagent Uric Acid FS TBHBA (DiaSys®) 
consisted of: 
Reagent 1 
- Phosphate buffer pH = 7,0 100 mmol/L 
- TBHBA (2,4,6-tribromo-3-hidroksibenzoic acid)1 mmol/L 
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Reagent 2 
- Phosphate buffer pH = 7,0100 mmol/L 
- 4aminoantypyrine 0,3 mmol/L 
- K4[Fe(CN6)]10  µmol/L 
- Peroxidase (POD) ≥ 2 kU/L 
- Uricase ≥ 30 U/L 
Standard: UricAcid 6mg/dl (375µmol/L) 
Reaction Principle: 
Urid Acid + H2O + O2     
Uricase     Allantoin + CO2 + H2O 
TBHBA + 4-aminoantypyrin + 2 H2O2 
  POD       Quinonimine 
+ 3H2O 
Methods 
Celecoxib was obtained from the identified Matrix 
Laboratories factory. The experimental animals used in this 
study were 75 white mice aged ± 3 months. Mice were 
grouped into 5 groups. Each group of mice was placed in a 
separate cage. Before the study was carried out, mice were 
adapted for 7 days and given standard food. Animals fulfill 
healthy requirements if during the observation they do not 
show significant weight changes (<10%) and visually do not 
show unhealthy symptoms. Production of preparations has 
been conducted as follows: 
Liver Homogenate 
- 100 grams of fresh cow liver washed, cut into small 
pieces, put in a blender tube, plus 25 ml distilled water, 
then blended until smooth, strain and put into a 
container. 
Making Na CMC 0,5% 
- Weighing Na-CMC as much as 0.125 g, then developed 
in distilled water as much as ± 2.5 ml then scoured 
homogeneously and sufficiently with distilled water until 
25 ml. 
Making Test solutions 
- The test solution was made by suspending Celecoxib in 
0.5% Na CMC, where the test substance was weighed 
according to the dose then added 0.5% Na CMC which 
had been developed, then crushed to a homogeneous 
period and diluted with distilled water until the volume 
needed. 
The dose of Celecoxib in humans is used 100, 200 and 400 
mg. After being converted into mice, it was obtained 0.26 
mg/20 g, 0.52 mg/20 g, and 1.04 mg/20 g. 
Data Analysis 
Data processed statistically using two-way Variance 
Analysis (ANOVA). If it is significantly different then 
proceed with Duncan's New Multiple Range Test 
(DNMRT) at the smallest significant difference level of 1% 
and 5% 
RESULTS AND DISCUSSION 
Table 1. The effect of Celecoxib administration on uric 
acid levels of average on average female white 
mice on days 7, 14, and 21 
Treatment 
Average serum of uric acid 
levels on the day Total 
Average 
± SE 
7 14 21 
I 2,32 ± 
0,28 
3,18 ± 
1,43 
4,37 ± 
0,57  
9,87 3,29 ±  
II 3,24 ± 
0,72 
4,03 ± 
1,50 
2,86 ± 
0,95  
10,13 3,37 ±  
III 1,67 ± 
0,55 
2,62 ± 
0,98  
2,76 ± 
1,61  
7,05 2,35 ±  
IV 2,97 ± 
0,99 
2,38 ± 
1,11  
2,19 ± 
0,35  
7,54 2,51 ±  
V 3,82 ± 
1,98 
1,97 ± 
0,61 
2,34 ± 
0,06  
8,13 2,71 ±  
Total 14,02 14,18 14,52 42,72 14,24 
Total  ± SE 2,80 ± 2,84 ± 2,90 ±  8,54 2,85 
Description : 
I = negative control group 
II = positive control group 
III = Celecoxib dose 0.26 mg / 20g BB 
IV = Celecoxib dose 0.52 mg / 20g BB 
V = Celecoxib dose 1.04 mg / 20g BB 
 
 
Figure 1. A bar chart of the relationship between serum 
uric acid levels and female white mice time 
In this study celecoxib was suspended in 0.5% Na-CMC 
which served as an inert carrier and celecoxib powder was 
evenly dispersed. Celecoxib suspension was given orally in 
experimental animals with various levels of doses of 0.26 
mg/20 g, 0.52 mg/20 g, and 1.04 mg/20 g. The use of 
Celecoxib dose was 0.26 mg/20 g, 0.52 mg/20 g, and 1.04 
mg/20 g is based on multiples of 2 (Zarraga & Schwarz, 
2007). 
In this study, experimental animals were given induction of 
the uric acid formation is the extract of cow liver as much 
as 0.5 mL/20 g orally for 7 consecutive days before 
treatment and continued during treatment, thus uric acid 
levels are high so that the effect of oral administration of 
celecoxib can be known. Selection of cow liver extract to 
increase uric acid levels in experimental animals because 
this cow liver contains 150-1000 mg of a purine for every 
100 g of cow liver. Celecoxib is given orally because this 
route of administration is more commonly used, easy to 
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administer, safe and it does not hurt experimental animals 
(Lascelles et al., 2007). 
Measurement of uric acid levels in the blood of mice is 
carried out by enzymatic methods which involve enzymatic 
uric acid oxidation reactions. The selection of the above 
measurement method is based on the simple process, 
namely the level of uric acid is directly known, is more 
sensitive and is a common method used in clinical 
laboratories (Pasalic et al., 2012). 
ANOVA test results (in table I), there was a significant 
effect on the decrease in blood uric acid levels in mice, 
where animals with the lowest doses of Celecoxib (0.26 
mg/20 g) showed a decrease in the highest blood uric acid 
levels of 2.35 mg/dl. Whereas with increasing doses of 0.52 
mg/20 g and 1.04 mg/20 g there was an increase in blood 
uric acid levels of mice, 2.51 mg/dl and 2.71 mg/dl. 
The results of this study, if calculated using statistics, we 
can compare the control group (+) with the celecoxib 
group with a dose of 0.26 mg/20 g, the celecoxib dose 
group 0.52 mg/20 g, and the celecoxib group 1.04 mg/20 g. 
Likewise, the control group (-) with celecoxib group dose 
0.26 mg/20 g, celecoxib group 0.52 mg/20 g, with significant 
differences between control (+) and control (-) with the 
dose of celecoxib have different abilities in reducing uric 
acid levels, on the other hand, giving celecoxib with other 
doses, there was no significant difference, there was no 
difference in reducing blood uric acid levels (Burns & 
Wortmann, 2012). However, after analyzing with Duncan 
's, it did not show any effect of giving celecoxib to blood 
uric acid levels of mice. 
 
CONCLUSION 
From the results of the study, it can be concluded that the 
administration of celecoxib at various doses (0.26 mg/20 g, 
0.52 mg/20 g, and 1.04 mg/20 g) does not affect uric acid 
levels in the blood for 21 days. 
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